May 12, 2026

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...

The ASCO Post

May 08, 2026

The Flu Vaccine Face-Off Ends in a Draw

Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season

Conexiant

May 05, 2026

AAP Updates Pediatric Office Emergency Readiness

Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.

Conexiant

May 04, 2026

Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

The ASCO Post

April 28, 2026

This Week’s Biopharma News: Wave of Antibody Approvals

FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars

The Medicine Maker

April 24, 2026

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

The ASCO Post

April 22, 2026

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

The ASCO Post

April 22, 2026

First-Line Zongertinib in Advanced HER2-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

The ASCO Post

April 22, 2026

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

The Pathologist

April 21, 2026

Are Respiratory Deaths Underreported?

Postmortem testing reveals gaps in respiratory virus diagnosis

The Pathologist